A Phase 1 Study Comparing AVP-786 With AVP-923

Completed · Phase 1

Conditions studied: Healthy Volunteer

In brief

To compare pharmacokinetics (PK) of AVP-786 (deuterated \[d6\] dextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) to AVP-923 (dextromethorphan hydrobromide \[DM\]/Q) at steady state.

Key facts

Study ID

NCT02336347

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

62

Starts

2014-05-01

Expected to finish

2015-03-01

Last updated by the study team

2026-04-28

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult males or females
• 18 - 60 years of age
• BMI 18 - 32 kg/m2

You may not qualify if…

• History or presence of significant disease
• History of substance abuse and/or alcohol abuse with the past 2 years
• Use of tobacco-containing or nicotine-containing products within 6 months
• Use of any prescription or the over-the-counter medications within 14 days

Where it is running

• Covance Dallas Clinical Research Unit — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.